Search research articles
Contact Us
Filters
Showing results (31-40 of 349) with videos related to
Page
of 35
Sort By:
BMJ (Clinical Research Ed.)
|
May 24, 2008
How to interpret figures in reports of clinical trials
Stuart J Pocock, Thomas G Travison, Lisa M Wruck
Trials
|
November 21, 2007
Figures in clinical trial reports: current practice & scope for improvement
Stuart J Pocock, Thomas G Travison, Lisa M Wruck
Nature Reviews. Cardiology
|
December 16, 2022
The need for new clinical trials of old cardiovascular drugs
Christopher B Granger, Stuart J Pocock, Bernard J Gersh
Epidemiologic Perspectives & Innovations : EP+I
|
October 19, 2010
Categorisation of continuous risk factors in epidemiological publications: a survey of current practice
Elizabeth L Turner, Joanna E Dobson, Stuart J Pocock
Journal of the American College of Cardiology
|
December 25, 2015
Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials
Stuart J Pocock, Tim C Clayton, Gregg W Stone
Journal of the American College of Cardiology
|
January 1, 2016
Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials
Stuart J Pocock, Tim C Clayton, Gregg W Stone
Journal of the American College of Cardiology
|
December 17, 2015
Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials
Stuart J Pocock, John J V McMurray, Tim J Collier
Journal of the American College of Cardiology
|
December 15, 2015
Making Sense of Statistics in Clinical Trial Reports: Part 1 of a 4-Part Series on Statistics for Clinical Trials
Stuart J Pocock, John J V McMurray, Tim J Collier
BMJ (Clinical Research Ed.)
|
February 9, 2011
Strategy for intention to treat analysis in randomised trials with missing outcome data
Ian R White, Nicholas J Horton, James Carpenter, et al.
Diabetes Care
|
June 28, 2006
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)
Robert H Knopp, Michael d'Emden, Johan G Smilde, et al.
Page
of 35
Search research articles
Search
Showing results (31-40 of 349) with videos related to
Sort By:
Page
of 35
BMJ (Clinical Research Ed.)
|
May 24, 2008
How to interpret figures in reports of clinical trials
Stuart J Pocock, Thomas G Travison, Lisa M Wruck
Trials
|
November 21, 2007
Figures in clinical trial reports: current practice & scope for improvement
Stuart J Pocock, Thomas G Travison, Lisa M Wruck
Nature Reviews. Cardiology
|
December 16, 2022
The need for new clinical trials of old cardiovascular drugs
Christopher B Granger, Stuart J Pocock, Bernard J Gersh
Epidemiologic Perspectives & Innovations : EP+I
|
October 19, 2010
Categorisation of continuous risk factors in epidemiological publications: a survey of current practice
Elizabeth L Turner, Joanna E Dobson, Stuart J Pocock
Journal of the American College of Cardiology
|
December 25, 2015
Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials
Stuart J Pocock, Tim C Clayton, Gregg W Stone
Journal of the American College of Cardiology
|
January 1, 2016
Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials
Stuart J Pocock, Tim C Clayton, Gregg W Stone
Journal of the American College of Cardiology
|
December 17, 2015
Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials
Stuart J Pocock, John J V McMurray, Tim J Collier
Journal of the American College of Cardiology
|
December 15, 2015
Making Sense of Statistics in Clinical Trial Reports: Part 1 of a 4-Part Series on Statistics for Clinical Trials
Stuart J Pocock, John J V McMurray, Tim J Collier
BMJ (Clinical Research Ed.)
|
February 9, 2011
Strategy for intention to treat analysis in randomised trials with missing outcome data
Ian R White, Nicholas J Horton, James Carpenter, et al.
Diabetes Care
|
June 28, 2006
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)
Robert H Knopp, Michael d'Emden, Johan G Smilde, et al.
Page
of 35